FN2 Earnings Intelligence
Cardinal Health, Inc. earnings overview
Latest Cardinal Health, Inc. (CAH) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Cardinal Health, Inc.
Cardinal Health's supplied earnings analysis supports a constructive operating trajectory: resilient pharmaceutical and specialty demand, FY27 EPS growth guidance of 13%-15%, and continued investment in automation and growth platforms. The case is tempered by tariff uncertainty, regulatory headwinds, and execution risk around integrations.
Cardinal Health, Inc.
Cardinal Health delivered strong Q3 FY2026 results with non-GAAP EPS up 35% to $3.17, beating consensus by 13.6%, driven by Specialty Solutions and at-Home/Nuclear growth. Management raised full-year EPS and free cash flow guidance. However, revenue of $60.9B missed the $62.1B consensus by 1.9%, SG&A investment accelerated, and a $184M Navista goodwill impairment underscored integration risk. The stock fell 4.9% on 3x normal volume despite the beat and guide raise, then recovered 2.0% in subsequent sessions. The investment thesis rests on Specialty platform expansion, theranostics capacity scaling, and GLP-1 demand tailwinds, offset by tariff uncertainty and margin pressure from rising operating costs.
Cardinal Health, Inc.
The supplied analysis supports a constructive but testable view: resilient pharmaceutical and specialty demand, expanding MSO platforms, and investment in At-Home Solutions and Nuclear & Precision Health are supporting earnings growth. The higher FY26 EPS outlook strengthens that case, while tariffs, acquisition integration, financing costs, and possible second-half deceleration argue for continued monitoring.
Cardinal Health, Inc.
The supplied analysis supports a constructive operating outlook: broad-based profit growth, strong pharmaceutical demand, acquisitions, and efficiency investments underpin the FY26 guidance raise. The thesis remains conditional on integration, reimbursement, pricing, and tariff execution.
Cardinal Health, Inc.
The supplied analysis supports a constructive near-term operating picture: broad segment growth, new customer onboarding, specialty demand and acquisitions outweighed current concerns. The longer-term case still depends on tariff mitigation, durable pharma margins and successful integration.
Cardinal Health, Inc.
The supplied analysis supports a constructive view of Cardinal Health's near-term operating trajectory: strong Pharma and Specialty demand, raised FY25 EPS guidance, and specialty-network integration offset weaker GMPD volumes and execution risks. The evidence is positive, but the thesis depends on sustained utilization, disciplined integration, and progress in GMPD.
Cardinal Health, Inc.
The supplied analysis supports a constructive but conditional view: Cardinal Health's Pharma and specialty growth, operational initiatives, and raised guidance strengthen the earnings trajectory, while GMPD costs and supply-chain risks remain important tests.
Cardinal Health, Inc.
Cardinal Health's FY24 results and raised FY25 EPS outlook support a constructive operating thesis, but the evidence is conditional: specialty growth, GMPD improvement, logistics investments, and cash generation are expected to offset a large contract loss. The key test is whether these offsets translate into sustained profit growth without the forecast revenue and cash-flow pressure overwhelming execution.
Get the CAH recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.